I advised a biopharmaceutical contract manufacturer investing in new capacity. From a detailed bottom-up analysis of products in the global large-molecule development pipeline, correlated against an analysis of the competition and technology trends, we highlighted a large and growing gap between demand for bio-manufacturing capacity and supply, over the period 2001–10. A presentation of these findings has been referenced widely, by Business Week and other publications.